No black box warning on record for Pimecrolimus

As of the latest FDA labeling reviewed, Pimecrolimus (PIMECROLIMUS) does not carry a black box warning. Standard warnings and precautions still apply — see the full Pimecrolimus medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications. ( 5.1 ) • Avoid treatment on malignant or pre-malignant skin conditions, as these can present as dermatitis. ( 5.2 ) • Should not be used in patients with Netherton’s Syndrome or skin diseases with a potential for increased systemic absorption. ( 5

No black box warning on record for Pimecrolimus

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications. ( 5.1 ) • Avoid treatment on malignant or pre-malignant skin conditions, as these can present as dermatitis. ( 5.2 ) • Should not be used in patients with Netherton’s Syndrome or skin diseases with a potential for increased systemic absorption. ( 5

Pimecrolimus Black Box Warning

No black box warning on record for Pimecrolimus

Other warnings & precautions

Pimecrolimus Black Box Warning

No black box warning on record for Pimecrolimus

Other warnings & precautions